156 related articles for article (PubMed ID: 27798672)
1. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
[TBL] [Abstract][Full Text] [Related]
2. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
[TBL] [Abstract][Full Text] [Related]
3. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract][Full Text] [Related]
5. PANCR, the PITX2 Adjacent Noncoding RNA, Is Expressed in Human Left Atria and Regulates PITX2c Expression.
Gore-Panter SR; Hsu J; Barnard J; Moravec CS; Van Wagoner DR; Chung MK; Smith JD
Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e003197. PubMed ID: 26783232
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
[TBL] [Abstract][Full Text] [Related]
7. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
8. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Sheng X; Guo Y; Lu Y
Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
[TBL] [Abstract][Full Text] [Related]
11.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
13. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
14. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
15. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
16. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
[TBL] [Abstract][Full Text] [Related]
17. Prediction efficiency of PITX2 DNA methylation for prostate cancer survival.
Luan ZM; Zhang H; Qu XL
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173224
[TBL] [Abstract][Full Text] [Related]
18. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
[TBL] [Abstract][Full Text] [Related]
19. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.
Schatz P; Dietrich D; Koenig T; Burger M; Lukas A; Fuhrmann I; Kristiansen G; Stoehr R; Schuster M; Lesche R; Weiss G; Corman J; Hartmann A
J Mol Diagn; 2010 May; 12(3):345-53. PubMed ID: 20304943
[TBL] [Abstract][Full Text] [Related]
20. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]